Leerink raised the firm’s price target on Dentsply Sirona (XRAY) to $17 from $16.50 and keeps a Market Perform rating on the shares. Heading into Q2 earnings, the firm is updating dental company estimates and publishing the results of its fourth semi-annual dental survey of 63 dental practitioners in the United States. There is clearly a budding interest in identifying incremental improvements across the dental space, even if each opportunity seems to be company-specific in what remains a still-challenged total dental end-market, Leerink says. The firm sees reasons to be positive on each stock in its coverage but also has some offsetting questions that limit too much constructiveness.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Cautious Outlook on DENTSPLY SIRONA Amid Strategic Focus and Market Challenges
- DENTSPLY SIRONA Issues $550M Junior Subordinated Notes
- Dentsply Sirona Announces $550 Million Notes Offering
- DENTSPLY SIRONA Amends Credit Facility for Flexibility
- Hold Rating on DENTSPLY SIRONA Amid Management Stabilization and Growth Uncertainties
